Cross-talk Between Statins and the Renin-angiotensin System

Hypercholesterolaemia and hypertension are major public health problems that are frequently treated with statins and renin-angiotensin system (RAS) blockades. Although the mechanisms of action for these two classes of drugs differ, both classes have beneficial effects on the vasculature. Experimental and clinical studies demonstrated that combined statins and RAS blockades improve endothelial function as reflected by improved flow-mediated dilation, improved fibrinolysis potential and reduced oxidant stress, inflammatory markers and insulin sensitivity. There is a strong scientific rationale for recommending combination therapy, especially statins and RAS blockades, to treat or prevent atherosclerosis and coronary heart disease. In this article, we address the mechanisms on the cross-talk between statins and RAS and discuss the rationale and importance of combination therapy with statins and RAS blockades in treating and preventing cardiovascular events.